Drug Pipeline Insights Report highlights rare liver diseases

Two new treatments for rare liver diseases currently in the pipeline include Bylvay (odevixibat), which was approved July 20, 2021 and maralixibat, which is expected to have an FDA decision on September 29, 2021. Bylvay treats pruritus associated with progressive familial intrahepatic cholestasis (PFIC) while maralixibat is in development for...